---
title: Corticosteroid Drugs
type: content
phase: 1
status: complete
priority: high
tags: [corticosteroids, glucocorticoids, mineralocorticoids, prednisone, hydrocortisone, HPA-axis, immunosuppression]
created: 2025-11-08
last_modified: 2025-11-08
---

# Corticosteroid Drugs

## Introduction

Corticosteroids are synthetic analogs of adrenal cortex hormones with potent anti-inflammatory, immunosuppressive, and metabolic effects. Understanding their diverse pharmacology, therapeutic uses, and significant adverse effects is crucial for safe and effective prescribing.

## Adrenal Cortex Physiology

### Zones and Hormones

**Adrenal Cortex** (3 zones):
1. **Zona glomerulosa** → **Mineralocorticoids** (aldosterone)
2. **Zona fasciculata** → **Glucocorticoids** (cortisol)
3. **Zona reticularis** → **Androgens** (DHEA, androstenedione)

**Mnemonic**: **GFR** = **G**lomerulosa (mineralocorticoids), **F**asciculata (glucocorticoids), **R**eticularis (androgens)
- "Salt, Sugar, Sex"

### Hypothalamic-Pituitary-Adrenal (HPA) Axis

**Normal Regulation**:
1. **Hypothalamus** → CRH (corticotropin-releasing hormone)
2. **Anterior pituitary** → ACTH (adrenocorticotropic hormone)
3. **Adrenal cortex** → **Cortisol**
4. **Negative feedback**: Cortisol → ↓CRH, ↓ACTH

**Circadian Rhythm**:
- **Peak cortisol**: Early morning (6-8 AM)
- **Nadir**: Midnight
- **Physiologic**: Mimics natural pattern

---

## Glucocorticoids

### Mechanism of Action

**Genomic (Primary, Delayed)**:
- **Bind intracellular glucocorticoid receptor (GR)**
- GR translocates to nucleus
- **Gene transcription** (hours to days):
  - **Transactivation**: ↑Anti-inflammatory proteins (lipocortin-1, IκB)
  - **Transrepression**: ↓Pro-inflammatory genes (NF-κB, AP-1)

**Non-Genomic (Rapid)**:
- Membrane effects (minutes)
- Important at high doses

### Pharmacologic Effects

**Anti-Inflammatory/Immunosuppressive** (Therapeutic):
- **↓Inflammatory mediators**: ↓Cytokines (IL-1, IL-2, IL-6, TNF-α), ↓prostaglandins, ↓leukotrienes
- **↓Immune cells**: ↓T-cell function, ↓B-cell function, ↓macrophage activation
- **↓Phospholipase A2** (via lipocortin-1) → ↓arachidonic acid → ↓prostaglandins, leukotrienes
- **↓Capillary permeability** → ↓edema
- **↓Fibroblast proliferation**

**Metabolic** (Adverse Effects):
- **Carbohydrate**: ↑Gluconeogenesis, ↑insulin resistance → **hyperglycemia**
- **Protein**: ↑Protein catabolism → **muscle wasting**, ↓wound healing, ↓bone formation
- **Lipid**: ↑Lipolysis (peripheral), ↑lipogenesis (central) → **central obesity**, ↑cholesterol
- **Calcium**: ↓Intestinal Ca2+ absorption, ↑renal Ca2+ excretion → **osteoporosis**

**Cardiovascular**:
- ↑Cardiac output, ↑vascular tone
- Permissive effect for catecholamines

**CNS**:
- Euphoria, insomnia, psychosis (high doses)

**Hematologic**:
- **Neutrophilia** (demargination)
- **Lymphopenia, eosinopenia, monocytopenia**

### Classification

**By Duration** (Based on biologic half-life):

**Short-Acting** (8-12 hours):
- **Cortisone**, **Hydrocortisone** (cortisol)

**Intermediate-Acting** (12-36 hours):
- **Prednisone**, **Prednisolone**, **Methylprednisolone**, **Triamcinolone**

**Long-Acting** (36-72 hours):
- **Dexamethasone**, **Betamethasone**

**By Potency** (Relative to hydrocortisone):

| Drug | Glucocorticoid Potency | Mineralocorticoid Potency | Duration |
|------|------------------------|---------------------------|----------|
| **Hydrocortisone** | 1 | 1 | Short |
| **Cortisone** | 0.8 | 0.8 | Short |
| **Prednisone** | 4 | 0.8 | Intermediate |
| **Prednisolone** | 4 | 0.8 | Intermediate |
| **Methylprednisolone** | 5 | 0.5 | Intermediate |
| **Triamcinolone** | 5 | 0 | Intermediate |
| **Dexamethasone** | 25-30 | 0 | Long |
| **Betamethasone** | 25 | 0 | Long |

**Key Points**:
- **Dexamethasone** most potent (25-30x hydrocortisone)
- **Long-acting** (dexamethasone) have **no mineralocorticoid activity** (pure glucocorticoid)
- **Hydrocortisone** has significant mineralocorticoid activity (use for adrenal insufficiency)

### Individual Agents

#### Hydrocortisone (Cortisol)

**Structure**: Identical to endogenous cortisol

**Formulations**: Oral, IV, topical

**Clinical Uses**:
1. **Adrenal insufficiency** (physiologic replacement) - **drug of choice**
2. **Acute adrenal crisis**
3. Anti-inflammatory (various conditions)
4. Topical (dermatologic)

**Dosing**:
- **Physiologic replacement**: 15-25 mg/day (divided BID-TID)
  - Morning dose larger (mimics circadian rhythm): 10-15 mg AM, 5 mg afternoon
- **Pharmacologic (stress)**: 100 mg IV q8h
- **Adrenal crisis**: 100 mg IV bolus, then 50-100 mg IV q6h

**Advantages**:
- **Mineralocorticoid activity** (can replace aldosterone partially)
- **Physiologic** (identical to cortisol)
- **Short half-life** (less HPA suppression with physiologic dosing)

**Note**: **Drug of choice for adrenal insufficiency** (both glucocorticoid and mineralocorticoid activity)

#### Prednisone

**Structure**: Synthetic analog (prednisolone prodrug)

**Conversion**: Prednisone (inactive) → **prednisolone** (active) in liver

**Formulations**: Oral only

**Clinical Uses**:
1. **Anti-inflammatory** (asthma, COPD, rheumatoid arthritis, inflammatory bowel disease)
2. **Immunosuppression** (organ transplant, autoimmune diseases)
3. **Allergic reactions**
4. **Hematologic** (ITP, hemolytic anemia, leukemia/lymphoma)
5. **Nephrotic syndrome**

**Dosing**:
- **Anti-inflammatory**: 5-60 mg/day
- **Immunosuppression**: 1-2 mg/kg/day
- **Pulse therapy**: 1000 mg/day × 3 days (severe)

**Advantages**:
- **Oral** (convenient)
- **Intermediate duration** (less HPA suppression than dexamethasone)
- **Inexpensive** (generic)
- **Most commonly prescribed systemic glucocorticoid**

**Note**: **Avoid in severe liver disease** (impaired conversion to prednisolone)

#### Prednisolone

**Structure**: Active form of prednisone

**Formulations**: Oral (liquid, tablet), ophthalmic

**Clinical Uses**: Same as prednisone
- **Preferred in liver disease** (no hepatic activation required)

**Note**: **Bioequivalent to prednisone** (unless liver disease)

#### Methylprednisolone

**Structure**: Methylated prednisolone (↑potency)

**Formulations**: Oral, IV (Solu-Medrol)

**Clinical Uses**:
1. **IV pulse therapy** (MS exacerbations, lupus nephritis, acute transplant rejection)
2. **Spinal cord injury** (high-dose protocol - controversial)
3. Anti-inflammatory (oral)

**Dosing**:
- **Pulse therapy**: 500-1000 mg IV daily × 3-5 days
- **Oral**: 4-48 mg/day

**Advantages**:
- **IV formulation** (high-dose pulse therapy)
- **Less mineralocorticoid activity** than prednisone (less fluid retention)

#### Dexamethasone

**Structure**: Fluorinated glucocorticoid

**Potency**: **25-30x hydrocortisone** (most potent)

**Formulations**: Oral, IV, IM, topical, ophthalmic

**Clinical Uses**:
1. **Cerebral edema** (tumors, trauma) - **drug of choice**
2. **Diagnostic** (dexamethasone suppression test)
3. **Antiemetic** (chemotherapy-induced)
4. **Croup** (pediatric)
5. **COVID-19** (severe, on oxygen) - **proven mortality benefit**
6. **Bacterial meningitis** (before antibiotics)
7. **Preterm labor** (fetal lung maturation)

**Dosing**:
- **Cerebral edema**: 10 mg IV, then 4 mg q6h
- **Antiemetic**: 8-20 mg
- **Croup**: 0.6 mg/kg PO/IM × 1
- **COVID-19**: 6 mg daily × 10 days
- **Fetal lung maturation**: 6 mg IM q12h × 4 doses (or 12 mg q24h × 2)

**Advantages**:
- **Most potent**
- **Long half-life** (36-72 hours)
- **No mineralocorticoid activity** (no fluid retention)
- **Crosses BBB well** (cerebral edema)
- **Less protein binding** (more free drug)

**Disadvantages**:
- **Greater HPA suppression** (long half-life)
- **More metabolic side effects**

**Dexamethasone Suppression Test** (Cushing's syndrome diagnosis):
- **Low-dose**: 1 mg at 11 PM → cortisol at 8 AM (<1.8 mcg/dL normal)
- **High-dose**: 8 mg → differentiate Cushing's disease vs. ectopic ACTH

#### Betamethasone

**Structure**: Stereoisomer of dexamethasone

**Potency**: 25x hydrocortisone

**Formulations**: Oral, IV, IM, topical

**Clinical Uses**:
1. **Fetal lung maturation** (preterm labor) - **drug of choice**
2. Anti-inflammatory

**Dosing**:
- **Fetal lung maturation**: 12 mg IM q24h × 2 doses

**Note**: **Preferred over dexamethasone for fetal lung maturation** (fewer injections)

### Adverse Effects

**Dosage-Dependent**:

**Metabolic**:
1. **Hyperglycemia, diabetes mellitus**:
   - ↑Gluconeogenesis, insulin resistance
   - Monitor glucose, especially diabetics

2. **Cushing's syndrome** (iatrogenic):
   - **Central obesity** ("buffalo hump", "moon face")
   - **Muscle wasting** (proximal myopathy)
   - **Skin**: Thin skin, easy bruising, striae, poor wound healing
   - **Hirsutism, acne**
   - Hypertension, edema

3. **Osteoporosis, fractures**:
   - ↓Osteoblast activity, ↑osteoclast activity
   - ↓Ca2+ absorption, ↑Ca2+ excretion
   - **Preventive measures**: Ca2+ (1200-1500 mg/day), vitamin D (800-1000 IU/day), bisphosphonates if indicated

4. **Growth retardation** (children):
   - Alternate-day dosing helps

**Cardiovascular**:
- **Hypertension** (mineralocorticoid effect, even weak)
- **Dyslipidemia** (↑cholesterol, ↑triglycerides)
- Fluid retention, edema

**Immunologic**:
- **Increased infection risk**:
  - Bacterial, viral, fungal (opportunistic)
  - **Reactivation**: TB, strongyloidiasis, hepatitis B
  - **Screen for latent TB** before chronic use
- **Impaired wound healing**

**GI**:
- **Peptic ulcer disease** (especially with NSAIDs):
  - Controversial if increases risk alone
  - **Clear ↑risk with NSAIDs**
  - Consider PPI if high risk

**Ophthalmic**:
- **Cataracts** (posterior subcapsular)
- **Glaucoma** (↑intraocular pressure)
- Exacerbation of herpes keratitis

**Psychiatric**:
- **Euphoria, insomnia** (common)
- **Mania, psychosis, depression** (high doses)
- **Mood changes, irritability**

**Dermatologic**:
- **Skin atrophy**, easy bruising, striae
- Poor wound healing
- Acne, hirsutism

**HPA Axis Suppression**:
- See below (major concern)

**Avascular Necrosis** (Osteonecrosis):
- Hip, knee (high doses)

**Myopathy**:
- Proximal muscle weakness

### HPA Axis Suppression

**Mechanism**:
- Exogenous glucocorticoids → **negative feedback** → ↓CRH, ↓ACTH
- **Adrenal atrophy** (chronic suppression)

**Risk Factors**:
- **Dose**: >20 mg prednisone equivalent/day (or >5 mg/day dexamethasone)
- **Duration**: >3 weeks (variable)
- **Time of day**: Evening doses worse (suppress morning surge)

**Clinical Significance**:
- **Adrenal insufficiency** if abruptly stopped or stressed (surgery, illness)
- **Life-threatening** (adrenal crisis)

**Prevention**:
- **Taper gradually** when discontinuing (see below)
- **Alternate-day dosing** (minimizes suppression, if possible)
- **Morning dosing** (mimics circadian rhythm)

**Recovery**:
- Months after stopping (variable)
- HPA axis function returns gradually

**Testing** (if unsure):
- **ACTH stimulation test** (cosyntropin 250 mcg)
  - Normal: Cortisol >18-20 mcg/dL at 30-60 min

### Glucocorticoid Withdrawal and Tapering

**Risks of Abrupt Withdrawal**:
1. **Adrenal insufficiency** (HPA suppression):
   - Fatigue, weakness, anorexia, nausea, hypotension
   - **Adrenal crisis** (if stressed)
2. **Disease flare** (underlying condition)
3. **Withdrawal syndrome**: Fatigue, myalgias, arthralgias (even if HPA intact)

**When to Taper**:
- **>3 weeks of use** at supraphysiologic doses
- **OR high-dose short course** (e.g., pulse therapy)

**Tapering Strategies**:

**General Principles**:
- **Slow taper** (weeks to months)
- **Faster initially** (high to moderate doses), **slower near physiologic**
- **Individualized** (dose, duration, indication)

**Example Taper** (Prednisone ≥40 mg/day):
1. **↓10 mg/week** until 20 mg/day
2. **↓5 mg/week** until 10 mg/day
3. **↓2.5 mg/week** until 5 mg/day
4. **↓1 mg/week or every 2 weeks** until discontinuation

**Very Slow Taper** (Long-term high-dose):
- ↓By 10-20% every 1-2 weeks (slower near physiologic)

**Physiologic Replacement** (If needed during taper):
- Prednisone 5 mg/day = Hydrocortisone 20 mg/day
- Continue until HPA recovery (months)

**Stress Dosing** (During taper or recent discontinuation):
- **Minor stress** (URI): Continue current dose
- **Moderate stress** (dental surgery): Hydrocortisone 50-100 mg/day × 1-2 days
- **Major stress** (surgery): Hydrocortisone 100 mg IV q8h × 24-48h, then taper

**Clinical Pearl**: **Never stop abruptly after >3 weeks of use** - risk of adrenal crisis

### Routes of Administration

**Systemic**:
- **Oral**: Most common (prednisone, dexamethasone)
- **IV**: High-dose (methylprednisolone, hydrocortisone, dexamethasone)
- **IM**: Depot preparations (rare)

**Local/Topical** (Minimize systemic effects):
- **Inhaled**: Asthma, COPD (budesonide, fluticasone, beclomethasone)
- **Topical**: Dermatologic (hydrocortisone, triamcinolone, betamethasone, clobetasol)
- **Intranasal**: Allergic rhinitis (fluticasone, mometasone)
- **Intra-articular**: Joint inflammation (methylprednisolone, triamcinolone)
- **Ophthalmic**: Eye inflammation (prednisolone, dexamethasone)

**Advantages of Local**:
- **Minimize systemic absorption**
- ↓HPA suppression
- ↓Adverse effects

**Note**: **Topical potency varies** (clobetasol > betamethasone > triamcinolone > hydrocortisone)

### Drug Interactions

**↑Glucocorticoid Metabolism** (↓effect):
- **CYP3A4 inducers**: Phenytoin, carbamazepine, rifampin, phenobarbital
- May require ↑glucocorticoid dose

**↓Glucocorticoid Metabolism** (↑effect):
- **CYP3A4 inhibitors**: Ketoconazole, itraconazole, ritonavir
- Risk of toxicity

**Pharmacodynamic**:
- **NSAIDs**: ↑GI bleed risk (additive)
- **Warfarin**: Variable effect (usually ↑INR initially, then ↓)
- **Vaccines**: Live vaccines contraindicated (immunosuppression)
- **Diuretics**: Hypokalemia (especially with mineralocorticoid activity)

### Contraindications (Relative)

- **Systemic fungal infections** (immunosuppression)
- **Active tuberculosis** (unless on TB treatment)
- **Herpes simplex keratitis** (ophthalmic use)
- **Live vaccines** (during immunosuppression)
- **Psychosis** (worsens - relative)

**Note**: Many conditions are **relative contraindications** (benefit vs. risk assessment)

---

## Mineralocorticoids

### Aldosterone Physiology

**Actions**:
- **Kidney** (principal cells of collecting duct):
  - ↑Na+ reabsorption (via ENaC)
  - ↑K+ secretion
  - ↑H+ secretion
  - ↑Water retention (follows Na+)
- **Net effect**: ↑BP, ↓K+, metabolic alkalosis

**Regulation**:
- **Renin-angiotensin-aldosterone system (RAAS)**
- Hyperkalemia (direct)
- ACTH (minor)

### Fludrocortisone

**Structure**: Synthetic mineralocorticoid

**Potency**:
- **Mineralocorticoid**: 125x cortisol
- **Glucocorticoid**: 10x cortisol (still has some)

**Pharmacokinetics**:
- Oral
- Long half-life (3.5 hours, but prolonged effect)

**Clinical Uses**:
1. **Primary adrenal insufficiency** (Addison's disease):
   - Combined with hydrocortisone (replace both cortisol and aldosterone)
2. **Orthostatic hypotension** (neurogenic):
   - ↑Blood volume, ↑BP
3. **Salt-wasting CAH** (congenital adrenal hyperplasia)

**Dosing**:
- **Adrenal insufficiency**: 0.05-0.2 mg/day
- **Orthostatic hypotension**: 0.1-0.4 mg/day

**Monitoring**:
- **Blood pressure** (hypertension)
- **Electrolytes** (hypokalemia)
- **Edema** (volume overload)

**Adverse Effects**:
- **Hypertension**
- **Hypokalemia** (K+ wasting)
- **Edema** (Na+/water retention)
- **Heart failure** (volume overload)

**Clinical Pearl**: **Essential for primary adrenal insufficiency** (Addison's) - cannot use glucocorticoid alone

---

## Clinical Pearls

1. **HPA suppression**: >20 mg prednisone × >3 weeks → **never stop abruptly** (taper)
2. **Hydrocortisone for adrenal insufficiency** (has mineralocorticoid activity)
3. **Fludrocortisone required** in primary adrenal insufficiency (aldosterone replacement)
4. **Dexamethasone for cerebral edema** (most potent, crosses BBB)
5. **Prednisone most commonly prescribed** oral glucocorticoid
6. **Osteoporosis prevention**: Ca2+, vitamin D, bisphosphonates (if long-term)
7. **Screen for latent TB** before chronic use (reactivation risk)
8. **PPI prophylaxis** if glucocorticoids + NSAIDs (GI bleed risk)
9. **Stress dosing** during illness/surgery if on chronic glucocorticoids (adrenal insufficiency risk)
10. **Morning dosing** preferred (mimics circadian rhythm, less HPA suppression)
11. **Live vaccines contraindicated** during immunosuppression
12. **Alternate-day dosing** minimizes HPA suppression (if possible)

---

## Key Takeaways

1. **Glucocorticoids**: Anti-inflammatory, immunosuppressive, metabolic effects
2. **Mechanism**: Bind GR → gene transcription (transactivation, transrepression)
3. **Potency**: Dexamethasone (25-30x) > methylprednisolone (5x) > prednisone (4x) > hydrocortisone (1x)
4. **Hydrocortisone**: Drug of choice for adrenal insufficiency (glucocorticoid + mineralocorticoid activity)
5. **Prednisone**: Most commonly prescribed oral glucocorticoid
6. **Dexamethasone**: Most potent, long-acting, no mineralocorticoid activity, cerebral edema
7. **HPA suppression**: Major concern, risk of adrenal crisis if abrupt withdrawal
8. **Tapering**: Required after >3 weeks supraphysiologic doses
9. **Adverse effects**: Cushing's syndrome, hyperglycemia, osteoporosis, infections, HPA suppression
10. **Fludrocortisone**: Mineralocorticoid for primary adrenal insufficiency
11. **Stress dosing**: Hydrocortisone 100 mg IV q8h during major stress (surgery)
12. **Prevention**: Ca2+, vitamin D, bisphosphonates (osteoporosis), TB screening, PPI (with NSAIDs)

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. Liu D, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013.
4. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001.
5. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021.
6. Endocrine Society Clinical Practice Guideline for Glucocorticoid-Induced Osteoporosis
